A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

NCT01984242 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

305

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
DRUG: Bevacizumab
DRUG: Sunitinib

Sponsor

Hoffmann-La Roche